Pimple Treatment's Future: Rambazole!

A study with Rambazole, a novel retinoic acid metabolism-blocking agent (RAMBA), determined that 94 % of subjects with moderate to severe acne cases treated with onemg of oral Rambazole once per day for 12 continuous weeks experienced decrease in total acne lesion count of more than 50 % and 35 % were considered "cleared or almost cleared".

This work tips to the production of this medication on future, since Barrier Therapeutics, Inc. reported positive Phase 2a data points for its oral formulation of Rambazole (TM) in the treatment of moderate to severe pimple and positive biological activity data points for its topical formulation of this product.

Experts explain that a subject must have had more than 90 % reduction in total lesion count to be seen as “cleared or almost cleared”. According to their report, inflammatory and non-inflammatory lesions responded evenly well to treatment. There were no serious effects related to the treatment with this new component. Only some patients of the group in work experienced dryness of skin and lips as non-serious side effects.

Geert Cauwenbergh, Ph.D., Chairman and Chief Executive Officer of Barrier Therapeutics, Inc. explained that “these positive Phase 2a results indicate that oral Rambazole is effective in moderate to extreme inflammatory acne, and that depending on the result of future, full scale clinical trials, this drug may one day fill the needs for safe and effective ways on how to get rid of pimples. These results further builds on our previously announced promising clinical data for oral Rambazole for psoriasis.